Ignite Creation Date:
2025-12-24 @ 3:02 PM
Ignite Modification Date:
2026-01-05 @ 6:10 PM
Study NCT ID:
NCT00237159
Status:
COMPLETED
Last Update Posted:
2011-03-23
First Post:
2005-10-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D011471', 'term': 'Prostatic Neoplasms'}], 'ancestors': [{'id': 'D005834', 'term': 'Genital Neoplasms, Male'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D005832', 'term': 'Genital Diseases, Male'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D011469', 'term': 'Prostatic Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077211', 'term': 'Zoledronic Acid'}], 'ancestors': [{'id': 'D004164', 'term': 'Diphosphonates'}, {'id': 'D063065', 'term': 'Organophosphonates'}, {'id': 'D009943', 'term': 'Organophosphorus Compounds'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D007093', 'term': 'Imidazoles'}, {'id': 'D001393', 'term': 'Azoles'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 284}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2002-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2011-03', 'lastUpdateSubmitDate': '2011-03-21', 'studyFirstSubmitDate': '2005-10-09', 'studyFirstSubmitQcDate': '2005-10-09', 'lastUpdatePostDateStruct': {'date': '2011-03-23', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2005-10-12', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2005-12', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Rate of skeletal complications', 'timeFrame': '3 months'}], 'secondaryOutcomes': [{'measure': 'Time to first skeletal complication', 'timeFrame': '3 months'}, {'measure': 'Bone pain', 'timeFrame': '3 months'}, {'measure': 'Patients´ satisfaction with treatment', 'timeFrame': '3 months'}, {'measure': 'Bone turnover parameters', 'timeFrame': '3 months'}]}, 'conditionsModule': {'keywords': ['Prostate cancer', 'Bone metastasis', 'Skeletal related event'], 'conditions': ['Prostate Cancer Patients With Bone Metastasis']}, 'descriptionModule': {'briefSummary': 'It is the aim of this clinical study to evaluate the skeletal-related event rate and tolerability of zoledronic acid in patients with prostate cancer patients and bone metastases.'}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion criteria:\n\n* Signed informed consent\n* A histologically confirmed diagnosis of carcinoma of the prostate\n* Therapy with hormonal treatments (medical or surgical castration)\n* Patients must have objective evidence of metastatic disease to bone.\n* Adequate liver function - serum total bilirubin concentration less than 1.5 x upper limit of normal value\n* ECOG performance status of 0, 1 or 2\n\nExclusion criteria:\n\n* Bone pain which requires strong narcotic therapy with centrally acting analgesic agents.\n* More than 3 bisphosphonate applications in patients history.\n* Previous Radiation therapy to bone (including therapeutic radioisotopes such as strontium 89) within 3 months prior to Visit 2.\n* Abnormal renal function as evidenced by\n\nA calculated creatinine clearance \\< 30 ml/minute. Creatinine clearance (CrCl) is calculated using the Cockcroft-Gault formula:\n\nCrCl= \\[140-age (years)\\] x weight (kg) {x 0.85 for female patients} \\[72 x serum creatinine (mg/dL)\\]\n\n* Corrected (adjusted for serum albumin) serum calcium concentration \\< 8.0 mg/dl (2.00 mmol/L) or ≥ 12.0 mg/dl (3.00 mmol/L)\n* Life expectancy \\< 6 months\n* Patients with evidence in the six months prior to randomization of severe cardiovascular disease (defined as uncontrolled congestive heart failure), hypertension refractory to treatment, or symptomatic coronary artery disease uncontrolled by treatment\n* Use of other investigational drugs (drugs not marketed for any indication) within 30 days prior to the date of randomization\n* Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.\n* Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants)\n\nOther protocol-defined inclusion and exclusion criteria may apply.'}, 'identificationModule': {'nctId': 'NCT00237159', 'briefTitle': 'Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis', 'organization': {'class': 'INDUSTRY', 'fullName': 'Novartis'}, 'officialTitle': 'Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis', 'orgStudyIdInfo': {'id': 'CZOL446EDE07'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'ZOL446', 'interventionNames': ['Drug: Zoledronic acid']}], 'interventions': [{'name': 'Zoledronic acid', 'type': 'DRUG', 'otherNames': ['ZOL446'], 'armGroupLabels': ['ZOL446']}]}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Novartis Pharmaceuticals', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Novartis Pharmaceuticals'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Novartis Pharmaceuticals', 'class': 'INDUSTRY'}, 'responsibleParty': {'oldNameTitle': 'External Affairs', 'oldOrganization': 'Novartis Pharmaceuticals'}}}}